Home > Press > Nanogen Issued Patent
Method described allows hybridization of DNA to be detected while conducting PCR
Nanogen Issued Patent for Method of Monitoring PCR Using Fluorescent Energy Transfer
San Diego, CA | July 07, 2005
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today it was issued Patent No. 6,911,310, "Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system" by the U.S. Patent and Trademark Office. The '310 patent relates to a method of monitoring polymerase chain reaction (PCR) amplification of nucleic acid (DNA or RNA) using fluorescent resonant energy transfer (FRET), which is an essential part of molecular diagnostics. Marking the 131st patent to issue to Nanogen, it is closely related to the patents previously issued that describe nanofabrication and self-assembly of photonic molecular structures.
The method described in the '310 patent allows hybridization of DNA to be detected while conducting PCR. The process begins with oligonucleotides that are labeled with donor or acceptor fluorophores, each fluorophore illuminating at a unique wavelength of light upon excitation. When a donor fluorophore is excited, it absorbs energy and transfers it to an acceptor fluorophore that is located within a specific distance to the donor. Energy transfer is permitted in this way when two oligonucleotides, one labeled with a donor fluorophore and one with an acceptor fluorophore, are hybridized to a target nucleic acid. Hybridization places the donor and acceptor fluorophores within transfer distance from each other. The transfer of energy brings a shift in the emitted wavelength that can be detected as a change in the color of the light. In the absence of a target, no energy transfer or change in color occurs. By measuring the emission wavelength that results from the energy transfer to the acceptor fluorophore, the presence of the target nucleic acid can be detected.
"Nanogen's research in nanotechnology and fluorescent energy transfer is the continuation of many years of work," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "Our growing intellectual property estate includes valuable technologies involving methods of fluorescent energy transfer that can be used for the creation of useful DNA diagnostic assay systems."
Nanogen's advanced diagnostics provide researchers, clinicians, physicians and patients worldwide with improved methods and tests that can predict, diagnose and ultimately help treat disease. Nanogen's products include real-time PCR reagents, the NanoChip(R) Molecular Biology Workstation platform for molecular diagnostic applications and its line of rapid point-of-care diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries.
For more information, please visit www.nanogen.com
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
Chief Financial Officer of Nanogen, Inc.
Media & Investor Relations Contact:
Atkins + Associates
Copyright © Nanogen
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Why Is Google Making Synthetic Arms? February 1st, 2015
DNA nanoswitches reveal how life's molecules connect: An accessible new way to study molecular interactions could lower cost and time associated with discovering new drugs January 30th, 2015
Made-in-Singapore rapid test kit detects dengue antibodies from saliva: IBN's MedTech innovation simplifies diagnosis of infectious diseases January 29th, 2015
Iranian Researchers Planning to Produce Edible Insulin January 28th, 2015
Why Is Google Making Synthetic Arms? February 1st, 2015
Nanomaterials Used to Reduce Heat Generated by LED Panels February 1st, 2015
Leader Describes Iran's Independence as Root Cause of Bullying Powers' Enmity February 1st, 2015
Performance Drop in Solar Cells Prevented by Nanotechnology February 1st, 2015
Industrial Nanotech, Inc. Announces New OEM Customer January 27th, 2015
Carbon nanotube finding could lead to flexible electronics with longer battery life January 14th, 2015
Liquipel Receives US Patent on Environmentally Friendly, Watersafe Treatment of Electronics: U.S. Patent Office Finds Watersafe™ Treatment Covers Cell Phones, Smart Phones, Tablets, Computers and More January 5th, 2015
New non-invasive method can detect Alzheimer's disease early: MRI probe technology shows brain toxins in living animals for first time December 22nd, 2014